Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
Enregistré dans:
Auteurs principaux: | Shahram Salek-Ardakani, Wenjing Yang, Sheng Ding, Shih-Hsun Chen, Pawel K Dominik, Jessica Stanfield, Nadia Kurd, Ryan Llewellyn, Jonathan Heyen, Carole Wang, Zea Melton, Thomas Van Blarcom, Kevin C Lindquist, Javier Chaparro-Riggers |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMJ Publishing Group
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3920fe53e43c44dd89bb0d4a1c33ff53 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
par: Lauric Haber, et autres
Publié: (2021) -
Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity
par: Ole A. Mandrup, et autres
Publié: (2021) -
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
par: Demet Candas-Green, et autres
Publié: (2020) -
Direct control of CAR T cells through small molecule-regulated antibodies
par: Spencer Park, et autres
Publié: (2021) -
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
par: S. Michael Chin, et autres
Publié: (2018)